Industry Reports

The Pharmaceutical Company Outlook to 2012

A Report by Datamonitor
The pharmaceutical industry faces a muted outlook with ethical sales forecast to grow at a 2006–12 CAGR of only 3.2%. The Big Pharma peer set is forecast to see sales increase at a 2.3% CAGR over 2006–12.

Pharma 2020: The vision

Which path will you take?

A Report by PricewaterhouseCoopers
By 2020, the context in which Pharma operates will be very different from that which prevails today. And one of the recurring motifs in all the shifts described is globalisation.

Gearing up for a global gravity shift

growth, risk and learning in the Asia pharmaceutical market

A Report by PricewaterhouseCoopers
The centre of gravity of the global pharmaceutical industry is shifting. Not only is Asia set to be the largest pharmaceutical market in the world but many Asian territories will be powerhouses of the industry. The shift started as economies grew and low cost manufacturing in the region expanded.

From blockbuster to nichebuster

A Report by Datamonitor
As pressures on the blockbuster model increase in terms of the perceived failure to harness R&D innovation, increased generic threat and greater P&R hurdles for me-too drugs, drug developers are turning to niche indications for future sales growth.

Combating Generics

Pharmaceutical Brand Defense for 2007

A Report by Cutting Edge Information
The most popular generics defense strategy employed in the past three years was the launch of new product formulations.

Pharma Risk Managers

ERM Is In Your Future

A Report by Forrester
Pharma risk managers and compliance professionals face increasing regulatory scrutiny and market pressures that amplify both business and operational risk.

Pressure Points

Risk Management in the Pharmaceuticals Industry

A Report by KPMG
There is no one “shrinkwrapped” solution; the approach to managing risk may differ from one company to another.

The Specialty Pharma Market Outlook

Key players, new company growth models and emerging opportunities

A Report by Business Insights
Specialty pharmaceutical companies can be defined as those companies that do not possess fully integrated value chains, and are not pure-play companies, involved in only one part of the value chain.

Looking Eastward

Tapping China and India to Reinvigorate the Global Biopharmaceutical Industry

A Report by The Boston Consulting Group, Inc.
As threats to their profitability loom, multinational pharmaceutical companies (MPCs) should take a strategic look at increasing their R&D offshoring to China and India.

Pharmaceutical Outsourcing Part 1

An Introduction to Contract Manufacturing Strategies

A Report by Datamonitor
Offshoring is not the only option to drive productivity and efficiencies.

Lifecycle Management Strategies

Maximizing ROI through indication expansion, reformulation and Rx-to-OTC switching

A Report by Business Insights
Maximizing ROI of brands through appropriate lifecycle management is a key objective for pharma companies as patent expiration results in steep sales declines.

A New Era Begins for India’s Clinical Research Market

A Report by Thomson CenterWatch
The clinical research outsourcing market in India grew to $70.5 million last year and will continue to climb.

Commercial Insight: Generic Cancer Market

New Legislation and a Wave of Patent Expiries to Transform the Market

A Report by Datamonitor
The generic cancer market is estimated to reach $10.9 billion by 2014 on account of patent expiries and opening up of biogenerics market worth billions.

The Outlook for Pharmaceuticals

Indonesia

A Report by Espicom Business Intelligence
Inexpensive production and labor, and increasing foreign investments are strengthening the Indonesian pharma market, despite its volatile socio-political system.